



Dissemination of Information March 2010

Dear ECONMED participants

The goal of this communication is to share with you a publication elaborated by Uruguay's [National Resources Fund](#) entitled "*Política y gestión de la Cobertura de Medicamentos de Alto Costo. Relevamiento de la experiencia internacional y respuesta del Fondo Nacional de Recursos*" part of the [technical publications](#) series at the FNR's Department of Highly Specialized Medicine.

- The report compiles extensive information on drugs and public financing mechanisms together with mentions to the introduction of new Medical Technologies from a Health Economics perspective based on cost-effectiveness. It also includes a detailed description of the last developments on the issue being promoted by the Uruguayan authorities framing them within an international perspective.
- The study includes an analysis of the current conditions of access to high-cost drugs combined with characterization of the [FNR](#) response to the challenge posed by rising pharmaceutical prices; an intervention articulated through the public health system, with emphasis on the rational selection of drugs and a system of prices and public financing of pharmaceutical products.
- It incorporates comparative tables of drugs covered by the FNR with regard to other countries including: Trastuzumab, Tacrolimus, Bevacizumab, Imatinib, and Interferon among others.
- Among the Annexes it shall be highlighted a set of legislative instruments that backs the operational work of the FNR as well as the [Comment No. 14 of the United Nations Committee](#) on the [International Covenant on Economic, Social and Cultural Rights \(ICESCR\)](#) on the Right to Health ([Article 12](#))

More information on the activities of the FNR and access to its publications can be found at <http://www.fnr.gub.uy/?q=node/96>

We encourage, once again, ECONMED participants to keep on using this listerv to exchange, disseminate and share materials, publications and best practices (or worst experiences) in the field of economic and legal regulation of pharmaceutical products.

